Uterine Cancer Treatment in India & UAE
Expert endometrial (uterine) cancer treatment — laparoscopic hysterectomy, radiation therapy, and immunotherapy. High cure rates in early-stage disease. Costs 65% lower in India.
Estimated cost: $3,500 – $7,500 · Average stay: 5–8 days
Uterine cancer — almost exclusively referring to endometrial cancer arising from the lining of the uterus — is the most common gynecologic malignancy in developed countries, with approximately 420,000 new cases annually worldwide. Fortunately, endometrial cancer is most often detected at an early stage because abnormal uterine bleeding prompts timely medical evaluation. Stage I disease has a 5-year survival exceeding 90%, making it one of the most curable cancers when caught early.
Modern endometrial cancer treatment has been transformed by molecular classification. The Cancer Genome Atlas (TCGA) defines four prognostic subgroups — POLE-ultramutated (excellent prognosis), MSI-hypermutated (immunotherapy-sensitive), copy number low, and copy number high (ESMO-ESGO high risk) — that now guide adjuvant therapy decisions more precisely than histologic grade alone.
The cornerstone of treatment is total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node staging. The laparoscopic or robotic approach is preferred at experienced centers, offering equivalent cancer outcomes with faster recovery and less pain than open surgery. Adjuvant treatment — vaginal brachytherapy, external beam radiation, and increasingly chemotherapy (paclitaxel + carboplatin) — is tailored to individual recurrence risk based on the molecular subgroup and surgical staging findings.
India's gynecologic oncology centers offer comprehensive endometrial cancer care with experienced robotic surgeons, dedicated radiation oncologists, and access to pembrolizumab immunotherapy for advanced or recurrent MSI-high disease.
Types and Staging of Uterine Cancer
Endometrial cancer has two major types:
Type 1 (endometrioid adenocarcinoma, 80% of cases): estrogen-driven, usually low grade, presents early with postmenopausal bleeding. Excellent prognosis in the majority of patients. Associated with obesity, diabetes, and polycystic ovarian syndrome.
Type 2 (serous, clear cell, carcinosarcoma): less common, not hormone-driven, higher grade, more aggressive behavior. Requires more aggressive treatment even at early stages.
FIGO staging:
- Stage I: Tumor confined to the uterus. 5-year survival: 85–95%.
- Stage II: Invasion into the cervical stroma. 5-year survival: 75–80%.
- Stage III: Extension to ovaries, fallopian tubes, vagina, or regional lymph nodes. 5-year survival: 50–65%.
- Stage IV: Invasion of bladder/bowel or distant metastasis. 5-year survival: 15–25%.
Who Needs Uterine Cancer Treatment?
Any woman with confirmed endometrial cancer requires surgical treatment. All stages except the most advanced are managed with surgery as the primary modality.
Surgical candidates: virtually all fit patients with stage I–III endometrial cancer. Laparoscopic or robotic total hysterectomy with bilateral salpingo-oophorectomy is the standard operation. Pelvic and para-aortic lymph node assessment (sentinel node biopsy or full dissection) is performed for intermediate and high-risk disease.
Adjuvant therapy candidates: determined by molecular subgroup, grade, stage, and depth of myometrial invasion. Low-risk stage I patients may require no adjuvant treatment. Intermediate-risk patients receive vaginal brachytherapy (VBT). High-risk patients receive external beam radiation ± chemotherapy (paclitaxel + carboplatin).
Advanced and recurrent disease: pembrolizumab is approved for MSI-high/MMR-deficient advanced or recurrent endometrial cancer (15–30% of endometrial cancers), with response rates of 40–57%. Lenvatinib + pembrolizumab is approved for non-MSI-high advanced disease, demonstrating improved overall survival.
Uterine Cancer Surgery and Adjuvant Treatment
Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy (TH/BSO) is performed under general anesthesia. Using a camera and small instruments inserted through 3–5 small incisions in the abdomen, the surgeon removes the uterus, cervix, ovaries, and fallopian tubes. The specimen is retrieved through the vagina.
Sentinel lymph node biopsy using indocyanine green (ICG) or technetium has replaced routine full lymphadenectomy at experienced centers. After ICG injection into the cervix at the start of surgery, the sentinel nodes in the pelvis are identified under infrared fluorescence and removed for examination. Sentinel node mapping detects nodal spread with high accuracy while avoiding the morbidity of complete lymph node dissection.
Post-surgical pathology determines adjuvant therapy. For POLE-ultramutated tumors: observation even if high grade. For MSI-hypermutated: pembrolizumab for advanced/recurrent disease. For high-grade or advanced disease: chemotherapy (paclitaxel + carboplatin, 6 cycles) ± external beam radiation.
Procedure Steps
- Endometrial biopsy with grade, histotype, and immunohistochemistry (ER, PR, MMR proteins, p53).
- Staging workup: CT chest/abdomen/pelvis; MRI pelvis for local staging; CA-125 for non-endometrioid histologies.
- Molecular testing: POLE mutation status, MMR/MSI testing, p53 status.
- Laparoscopic or robotic TH/BSO with sentinel lymph node mapping under ICG fluorescence.
- Intraoperative frozen section of the uterus to assess depth of myometrial invasion if sentinel node mapping is used.
- Final pathology with FIGO staging, grade, lymphovascular invasion, and sentinel node results.
- Adjuvant therapy: VBT alone (low-risk), EBRT ± VBT (intermediate risk), chemotherapy ± EBRT (high risk).
- Surveillance: pelvic examination every 3 months for 2 years; CT if symptomatic or high-risk.
Uterine Cancer Treatment Approaches
Laparoscopic / Robotic Hysterectomy
Minimally invasive removal of the uterus, cervix, and ovaries through small abdominal incisions. Equivalent cancer outcomes to open surgery with significantly less pain, shorter hospital stay (2–3 days), and faster return to normal activity. The preferred approach at high-volume gynecologic oncology centers.
Cost: $3,500 – $7,500
Vaginal Brachytherapy (VBT)
Internal radiation delivered via a vaginal cylinder applicator to reduce risk of vaginal vault recurrence after hysterectomy. An outpatient procedure (2–3 fractions over 1–2 weeks). Recommended for intermediate-risk stage I endometrial cancer.
Cost: $1,500 – $3,000 (full course)
Paclitaxel + Carboplatin Chemotherapy
Six cycles of the taxane-platinum doublet for high-risk or advanced endometrial cancer. Active against aggressive histologies (serous, clear cell, carcinosarcoma) and high-grade endometrioid tumors with adverse features.
Cost: $600 – $1,500 per cycle
Pembrolizumab (MSI-High Disease)
Anti-PD-1 immunotherapy for MSI-high/MMR-deficient advanced or recurrent endometrial cancer. Response rates of 40–57% including durable complete remissions. Available in India at significantly reduced cost.
Cost: $1,500 – $3,000 per infusion
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $3,500 – $7,500 — Save 65–75%
UAE — $6,000 – $12,000 — Save 50–60%
USA / UK — $15,000 – $40,000+ — Baseline
Uterine cancer surgery in India costs $3,500–$7,500 — roughly 65–75% less than the USA. India's leading gynecologic oncology centers are equipped with robotic surgical systems and ICG fluorescence sentinel mapping technology. Adjuvant chemotherapy and brachytherapy are available at similarly reduced costs, making comprehensive treatment accessible for international patients.
Recovery & Follow-up
Hospital stay after laparoscopic hysterectomy is 2–3 days. Return to light daily activities is possible within 1–2 weeks; full recovery takes 4–6 weeks. Brachytherapy is administered as outpatient sessions and causes minimal disruption. If chemotherapy is needed, it starts 4–6 weeks after surgery and runs for 4.5 months. Menopausal symptoms from bilateral oophorectomy are managed with non-hormonal supportive measures.
Recovery Tips
- Pelvic rest (no sexual intercourse, tampons, or heavy lifting) for 6–8 weeks after hysterectomy.
- Walk daily starting the day after surgery to prevent blood clots.
- Manage menopausal symptoms after oophorectomy: vaginal dryness, hot flashes — discuss non-hormonal management with your oncologist.
- Take all prescribed medications and attend all blood count checks during chemotherapy.
- Report any abnormal vaginal bleeding, pelvic pain, or leg swelling promptly.
Risks & Complications
Hysterectomy risks include bleeding, infection, injury to bladder or ureter, and deep vein thrombosis. Lymph node dissection adds lymphedema risk (minimized by sentinel node approach). Brachytherapy may cause vaginal dryness or stenosis. Chemotherapy risks include bone marrow suppression, nausea, hair loss, and neuropathy. All are managed proactively by the oncology team.
Why GAF Healthcare
Gaf Healthcare connects uterine cancer patients with India's leading gynecologic oncology programs. Our partner hospitals maintain da Vinci robotic systems for minimally invasive hysterectomy, offer comprehensive molecular testing, and deliver all adjuvant therapies including brachytherapy and immunotherapy. We coordinate rapid surgical scheduling and all follow-up care planning.
Frequently Asked Questions
What is the cure rate for uterine cancer in India?
Stage I endometrial cancer — the most common presentation — has a 5-year survival of 85–95% after laparoscopic hysterectomy. Stage II has 75–80% survival. India's gynecologic oncology centers achieve outcomes equivalent to leading international programs.
Is robotic surgery available for uterine cancer in India?
Yes. Several of India's premier cancer hospitals (Tata Memorial Mumbai, Apollo, Fortis, Medanta) offer da Vinci robotic-assisted hysterectomy for uterine cancer. Robotic surgery provides superior dexterity in the narrow pelvic space with equivalent oncologic outcomes and faster recovery than conventional laparoscopy.
Do I need chemotherapy after hysterectomy for uterine cancer?
It depends on the risk category. Stage IA, grade 1–2 endometrioid cancer generally requires no adjuvant treatment or only vaginal brachytherapy. High-risk features — grade 3, serous histology, deep myometrial invasion, lymphovascular invasion, positive lymph nodes — indicate adjuvant chemotherapy with paclitaxel + carboplatin ± radiation.
What is MMR testing and why is it important in uterine cancer?
MMR (mismatch repair) protein testing identifies uterine cancers that are deficient in DNA repair (MMR-deficient or MSI-high). These cancers, found in 15–30% of endometrial cases, are highly sensitive to pembrolizumab immunotherapy. MMR testing is standard in all advanced and recurrent uterine cancers.
How long will I stay in India for uterine cancer treatment?
Laparoscopic hysterectomy requires 2–3 days in hospital. Recovery to safe travel is typically 10–14 days. If adjuvant brachytherapy alone is needed, additional 1–2 weeks are required. If chemotherapy is indicated, the 6-cycle course runs for 4.5 months — many patients return home between cycles.